Earnings ·
Novo Nordisk raises full-year outlook on GLP-1 momentum, Q3 adjusted operating profit up 27% at CER
NONOFNovo Nordisk A S
Novo Nordisk raised its full-year adjusted sales and operating profit growth expectations to -2% to +2% at constant exchange rates, citing continued momentum in GLP-1 products. Third-quarter adjusted operating profit increased 27% at CER to DKK 31,720 million, driven by obesity volume growth and a favorable comparison base after prior-year transformation costs. However, reported operating profit fell 9% at CER due to DKK 8.7 billion in non-cash impairment charges related to the ziltivekimab program and manufacturing network right-sizing. The company also highlighted strong commercial uptake of Wegovy pill launches across eight markets globally. Novo Nordisk A/S is a global healthcare company focused on discovering, developing, and delivering innovative medicines for patients with serious chronic diseases.